MONTENEGRO

BASIC COUNTRY DATA

Total Population: 631,490  
Population 0-14 years: 19%  
Rural population: 41%  
Population living under USD 1.25 a day: no data  
Population living under the national poverty line: 4.9%  
Income status: Upper middle income economy  
Ranking: High human development (ranking 54)  
Per capita total expenditure on health at average exchange rate (US dollar): 617  
Life expectancy at birth (years): 74

BACKGROUND INFORMATION

Montenegro is endemic for leishmaniasis. From 1992 to 2009, 55 cases of VL were reported, and one case of CL. Underreporting is common; a survey between 1992-1995 showed that out of 19 children treated, only 8 were officially reported. 40% of cases occur in children under 5, and 67% in children between 0 and 15 years old. 62% of cases are male.

From 2006-2009, serological surveys of clinically suspect dogs coming from VL endemic areas found a 58% average rate of infection.

There are no reported cases of HIV/Leishmania co-infection.

PARASITOLOGICAL INFORMATION

<table>
<thead>
<tr>
<th>Leishmania species</th>
<th>Clinical form</th>
<th>Vector species</th>
<th>Reservoirs</th>
</tr>
</thead>
<tbody>
<tr>
<td>L. infantum</td>
<td>ZVL</td>
<td>P. neglectus</td>
<td>Canis familiaris</td>
</tr>
</tbody>
</table>
MAPS AND TRENDS

Visceral leishmaniasis

Cutaneous leishmaniasis

No information available.

Visceral leishmaniasis trend
CONTROL

The notification of leishmaniasis is mandatory in the country. There is no national leishmaniasis control program, no leishmaniasis vector control program and no leishmaniasis reservoir control program.

DIAGNOSIS, TREATMENT

Diagnosis:
VL: microscopic examination of bone marrow aspirate, IFAT and ELISA.

Treatment:
VL: antimonials, 20 mg Sb⁵/kg/day. Mortality rate 0%.

ACCESS TO CARE

No information.

ACCESS TO DRUGS

Antimonials are not registered in Montenegro and no drugs for leishmaniasis are included in the essential drugs list. Patients are known to privately purchase antimonials (Glucantime, Sanofi) in Italy. Antimonials are not included in the list of drugs that are reimbursed by the National Health Insurance.

SOURCES OF INFORMATION